NCT01334151View on ClinicalTrials.gov

Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Diabetes Mellitus Type 1
Interventions
DRUG

Insulin LISPRO

Single doses of: 0.15 U/kg

DRUG

recombinant human insulin

Single doses of: 0.15 U/kg

Trial Locations (1)

91911

Profil Institute for Clinical Research, Inc. (PICR), Chula Vista

Sponsors

Lead Sponsor

Biodel
All Listed Sponsors
lead

Biodel

INDUSTRY

NCT01334151 - Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes | Biotech Hunter | Biotech Hunter